Valuation : Structure Therapeutics Inc.

Market Cap 337.58Cr 290.45Cr 272.57Cr 249.38Cr 465.45Cr 32TCr 469.14Cr 3.22TCr 1.26TCr 16TCr 1.27TCr 1.24TCr 53TCr P/E 2026 *
-29.2x
P/E 2027 * -21.6x
Enterprise Value 240.87Cr 207.24Cr 194.48Cr 177.93Cr 332.1Cr 23TCr 334.73Cr 2.3TCr 895.95Cr 12TCr 904.5Cr 884.77Cr 37TCr EV / Sales 2026 *
62.6x
EV / Sales 2027 * 67,593x
Free-Float
94.05%
Yield 2026 *
-
Yield 2027 * -
1 day-0.96%
1 week-3.82%
Current month+3.11%
1 month-2.11%
3 months+26.24%
6 months-24.90%
Current year-31.93%
1 week 45.1
Extreme 45.1
48.64
1 month 45.1
Extreme 45.1
55.6
Current year 35.78
Extreme 35.78
94.77
1 year 19.5
Extreme 19.5
94.9
3 years 13.22
Extreme 13.22
94.9
5 years 13.22
Extreme 13.22
94.9
10 years 13.22
Extreme 13.22
94.9
Manager TitleAgeSince
Director of Finance/CFO 48 01/05/2022
Chief Executive Officer 62 01/05/2019
Chief Operating Officer 49 15/04/2026
Director TitleAgeSince
Director/Board Member 62 01/02/2019
Chairman 68 19/01/2022
Director/Board Member 66 29/03/2022
Date Insider Type Main position Quantity % Market Cap. Importance
01/09/26 Exercice

Chief Technology Officer

65,329 0.0467%
18/08/26 Exercice

Chief Technology Officer

43,329 0.0310%
04/08/26 Exercice

Chief Technology Officer

43,329 0.0310%
Change 5-day change 1-year change 3-year change Capi.($)
-0.96%-3.82%+140.18%+61.18% 337.58Cr
+0.41%-2.07%+41.26%+95.40% 6.9TCr
-1.16%+0.74%+42.83%+89.89% 6.63TCr
+0.04%+4.36%-11.72%+459.54% 2.77TCr
-0.90%-7.65%+2.45%-15.50% 2.58TCr
-3.00%-2.90%+39.40%+9.41% 2.65TCr
-0.50%+1.86%+25.85%-17.54% 2.04TCr
+3.45%-13.46%+222.69%+389.50% 1.76TCr
-1.49%-4.88%-0.41%+530.26% 1.51TCr
+1.03%+7.00%+59.98%+160.03% 1.47TCr
Average -0.31%-1.62%+56.25%+176.22% 2.87TCr
Weighted average by Cap. -0.39%-0.87%+42.82%+147.25%

Financials

2026 *2027 *
Net sales 3.85Cr 3.31Cr 3.11Cr 2.84Cr 5.3Cr 363.58Cr 5.35Cr 37Cr 14Cr 185.8Cr 14Cr 14Cr 598.4Cr 41.67T 35.85T 33.64T 30.78T 57.45T 39.39L 57.91T 4L 2L 20.13L 2L 2L 64.83L
Net income -31Cr -27Cr -25Cr -23Cr -43Cr -2.92TCr -43Cr -294.68Cr -114.76Cr -1.49TCr -115.86Cr -113.33Cr -4.8TCr -48Cr -41Cr -38Cr -35Cr -66Cr -4.49TCr -66Cr -454.04Cr -176.82Cr -2.3TCr -178.51Cr -174.61Cr -7.4TCr
Net Debt -97Cr -83Cr -78Cr -71Cr -133.35Cr -9.14TCr -134.41Cr -923.77Cr -359.75Cr -4.67TCr -363.19Cr -355.26Cr -15TCr -56Cr -48Cr -45Cr -41Cr -77Cr -5.29TCr -78Cr -534.12Cr -208.01Cr -2.7TCr -209.99Cr -205.41Cr -8.7TCr
Logo Structure Therapeutics Inc.
Structure Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing oral small molecule treatments for chronic metabolic and cardiopulmonary conditions with significant unmet medical needs. Its programs include Aleniglipron (GSBR-1290), ACCG-2671, GIP and GCG Receptor Oral Small Molecule Obesity Programs, ANPA-0073, and LTSE-2578. Its Aleniglipron is an oral and biased small molecule agonist of GLP-1R, a validated GPCR drug target for obesity. ACCG-2671 is an oral small molecule amylin receptor agonist for obesity. ANPA-0073 is a biased agonist targeting the apelin (APJ) receptor agonist. Its LTSE-2578, an Oral Small Molecule LPA1R Antagonist for IPF. It is developing an antagonist that targets lysophosphatidic acid 1 receptor (LPA1R), a GPCR implicated in responses to tissue injury and pro-fibrotic processes, for the treatment of IPF. It is developing oral incretins for potential combination therapy with GLP-1R or amylin candidates.
Employees
281
Date Price Change Volume
03/26/03 $47.34 -0.96% 6,21,486
02/26/02 $47.80 +1.42% 10,64,737
01/26/01 $47.13 +2.66% 8,16,626
31/26/31 $45.91 -3.08% 13,94,959
28/26/28 $47.37 -3.76% 6,01,773
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
16
Last Close Price
47.34USD
Average target price
104.77USD
Spread / Average Target
+121.31%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. GPCR Stock